AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02027324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine Group
Description: 10% Povidone-Iodine for surgical antisepsis according to manufacturer's instructions.
Study NCT00495794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-based intervention
Description: Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms
Study NCT01960036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness in Body-oriented Therapy
Study NCT01960036 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Womens Health Education
Study NCT00749489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: Patients assigned to the intervention group will have a femoral nerve block administered by the attending emergency department physician. Twenty-four hours after the femoral nerve block or at the time of surgery, an anesthesiologist will insert a continuous fascia iliaca block. Both procedures (femoral nerve block and fascia iliaca blocks) are standard anesthetic techniques that are used in orthopedic procedures but their efficacy as compared to standard opioid therapy has not been evaluated in controlled clinical trials in hip fracture. The medications that will be used in each procedure are as follows: 1) femoral nerve block: 0.5% bupivacaine with 1:300,000 epinephrine; 2) fascia iliaca block: 0.2% ropivacaine will be infused at 5ml/hr.
Study NCT02254616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy with tDCS
Description: The MTtDCS group will receive a 20-minute tDCS at 1.5 mA current intensity per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
Study NCT02254616 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Therapy with sham-tDCS
Description: The MTtDCS(m) group will receive a 20-minute sham-tDCS per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
Study NCT02254616 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Therapy
Description: The MT group will receive a 60-minute MT per session followed by a 30-minute functional training.
Study NCT01160913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous wound
Study NCT03659136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xentuzumab
Description: Intravenous infusion
Study NCT02454855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral supplementation with placebo (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).
Study NCT00492440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-7
Study NCT03659136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study NCT03659136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus
Description: Tablet
Study NCT00492440 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Study NCT00492440 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Study NCT00492440 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Study NCT02254616 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training.
Study NCT01361724 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical therapy
Description: Physical therapy program for people with PD--one on one with a PT
Study NCT01361724 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group Exercise Class
Description: The participant will be in an exercise class for 3 days a week for 4 weeks.
Study NCT01361724 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home Program
Description: The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
Study NCT00492440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Study NCT02404324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescription of spectacles
Description: All children are prescribed full optical correction of refractive errors with special attention to astigmatism up to 0.5 Dptr to achieve maximal clear image on the retina of both eyes.If necessary, direct occlusion or penalization are administered to the children.
Study NCT02020681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curodont Repair
Description: Self-assembling peptide, biomimetic re-mineralisation
Study NCT02020681 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation of Curodont Repair without the peptide P11-4
Study NCT02020681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride
Description: Single application on day D90
Study NCT02020681 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Single application on day D90
Study NCT02013999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality program for upper extremity rehabilitation
Study NCT02013999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard occupational therapy
Study NCT01359865 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Lumbar Plexus Block
Description: lumbar plexus block followed by a general anesthetic. The lumbar plexus block will be performed by an attending anesthesiologist using ultrasound guidance (for measuring the depth of the psoas compartment) and nerve stimulation. A standardized block solution of 30 mL 0.5% ropivacaine will be injected in fractionated doses when a quadriceps muscle twitch is present to nerve stimulation at \<0.50 mA. Fifteen minutes after block completion, the block's effectiveness will be evaluated with an ice test.
Study NCT03917394 — intervention group
Intervention type: DRUG
Intervention: rHuEPO
Description: rHuEPO was administrated daily with 10000 IU or 20000 IU
Study NCT03917394 — intervention group
Intervention type: DRUG
Intervention: Iron sucrose
Description: Iron sucrose was administrated daily with 100mg or 200mg
Study NCT03092141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Study NCT03950505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
Description: All participants will be treated with Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) for 24 weeks. Patients who have not been prescribed any other anti-diabetic drugs at least for 12 weeks and whose HbA1c ranges from 6.5\~8.5%, can be enrolled. If Patients has been prescribed metformin as monotherapy, they have to substitute metformin with nesinaact 25-15 for enrollment.
Study NCT01558206 — intervention group
Intervention type: OTHER
Intervention: Pulmonary artery CT Angiography
Description: Performing Pulmonary artery CT Angiography for patients with signs and symptoms in favor of PTE.
Study NCT00492440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Study NCT00492440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Study NCT00492440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00492440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT04248530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: DENEX catheter is a device to treat resistant hypertension which delivers high-frequency energy through the three electrodes connected to the catheter in order to cauterize sympathetic nerve bundle.
Study NCT00727012 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: mitral valve repair (SJM® Rigid Saddle Ring)
Description: mitral valve repair due to mitral degenerative or functional disease
Study NCT01558206 — intervention group
Intervention type: OTHER
Intervention: Emergency Bedside Ultrasonography of chest
Description: Performing Emergency Bedside Ultrasonography of chest at the time of presentation for patients with signs and symptoms in favor of PTE.
Study NCT02398643 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary Education (PE)
Description: Patients enrolled in PE will undergo focused education sessions following discharge from hospital.
Study NCT02398643 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients enrolled in usual care will receive general education sessions following discharge from hospital.
Study NCT04686396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix
Description: Demineralized bone matrix
Study NCT02211417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral DS107
Study NCT02211417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01810302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine hydrochloride
Description: Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
Study NCT01810302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preservative-free normal saline
Description: Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
Study NCT01458691 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Steroid injection into the glenohumeral joint
Description: * Group: Steroid~* Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 25-gauze spinal needle~* The intra-articular injections were performed using ultrasonographic guidance.
Study NCT01458691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic PRP injection into the glenohumeral joint
Description: * Group: Allogeneic PRP~* Total volume of injection drugs: 4ml~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 25-gauze spinal needle~* The intra-articular injections were performed using ultrasonographic guidance.
Study NCT04046289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Low Calcium Milk
Description: 50 mg calcium/day
Study NCT00005828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extract
Study NCT01969903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex injection
Study NCT03659136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Tablet
Study NCT03659136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exemestane
Description: Tablet
Study NCT01848132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide: intravenous, 750 mg/m2, day 1
Study NCT03659136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Tablet
Study NCT04255641 — intervention group
Intervention type: OTHER
Intervention: time lapse analysis
Description: grading of the embryos before freezing using time lapse/
Study NCT03167528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: Relaxation
Study NCT03167528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Hypnosis
Study NCT04046289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Regular Calcium Milk
Description: 400 mg/day
Study NCT04046289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Probiotic 1
Description: regular calcium milk + probiotic
Study NCT04046289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Probiotic 2
Description: regular calcium milk + probiotic
Study NCT03515499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Subjects in the treatment arm will be paid up to $1 per day over 3 months for perfect medication adherence. Adherence rates will then be compared between the 2 groups.
Study NCT03515499 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication device monitoring and reminders
Description: Bluetooth enabled sensor device for medication reminders, as well as mobile app to track medication use.
Study NCT01848132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Adriamycin:intravenous, 50 mg/m2, day 1
Study NCT01848132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Adriamycin:intravenous, 50 mg/m2, day 1
Study NCT03167528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic gymnastics
Description: holistic gymnastics
Study NCT03167528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: TENS
Study NCT02935790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-241
Description: tablet
Study NCT02935790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: infusion
Study NCT02935790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: infusion
Study NCT03167528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sophrology
Description: Sophrology
Study NCT03263416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dedicated and coordinated follow-up
Description: * Coordinated follow-up performed by a dedicated nurse with consultations (before treatment initiation and during treatment) and a telephone follow-up during treatment period~* Pharmaceutical conciliation before treatment initiation made by the Center Pharmacist~* Completion of QLQ-C30 and GIRERD questionnaires
Study NCT03515499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication device monitoring and reminders
Description: Bluetooth enabled sensor device for medication reminders, as well as mobile app to track medication use.
Study NCT03263416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard follow-up
Description: - Completion of QLQ-C30 and GIRERD questionnaires
Study NCT05264194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suturing technique
Description: The technique (subcuticular or transcutaneous) that will be used to close skin post-surgery.
Study NCT04738916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training
Description: Whole body vibration (WBV) is a form of treatment that has been shown to have an important role in increasing neuromuscular performance, improving muscular strength, balance. The technique involves standing and holding positions, or performing prescribed exercises, on a platform that is vibrating at a programmed frequency, amplitude, and magnitude of oscillationWhole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform.
Study NCT02818777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol
Description: Purified CBD, is a strawberry flavored liquid, in sesame oil, provided as 100 mg/ml, extracted from high CBD plant material.~A component of cannabis that has evidence suggesting it is relatively safe and perhaps neuroprotective, reduces tremor, anxiety and psychosis and is well tolerated in PD. Besides limiting the psychoactive effect of THC, studies support that CBD has anti-inflammatory, anticonvulsant, anti-oxidant, anxiolytic and antipsychotic properties.
Study NCT02325011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex® (Treatment A)
Description: Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
Study NCT02325011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex® and fluconazole concomitantly (Treatment B)
Description: Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.~Fluconazole 200 mg twice daily (BID) for two days, will be administered at the following time points relative to the Day 1 Sativex dose: 1 hour pre-dose, and approximately 11, 24, and 36 hours post-dose.
Study NCT00895310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole is taken three times a day by mouth.
Study NCT00895310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone is taken by mouth 20 mg every morning and 10 mg every evening.
Study NCT00411814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK679586
Description: Active Drug
Study NCT00411814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT00240500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.
Study NCT01315444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stop PPI gradually
Study NCT01025830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triomune
Description: Stavudine (40mg) Lamivudine (150mg) Nevirapine (200mg)All twice a day
Study NCT01025830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zerit/Epivir/Viramune
Description: Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.
Study NCT03642730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TransThoracic Echocardiography imaging
Description: ultrasound scanning
Study NCT02493075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The operator blinded to the contact force data or not.
Description: CF guided group: ablation will be performed with the guidance of real-time CF, ablation time, FTI, etc. CF will be controlled in the range of appropriate CF, which has been defined in phase I. Circumferential PV ablation will be performed orderly, isolated segment, acute reconnected segment , and unisolated segment will be also identified as described in phase I.~Usual ablation group:~Operator will be blinded to CF data, the procedure performance is the same as described in phase I.
Study NCT02493075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The operator blinded to the contact force data or not.
Description: CF guided group: ablation will be performed with the guidance of real-time CF, ablation time, FTI, etc. CF will be controlled in the range of appropriate CF, which has been defined in phase I. Circumferential PV ablation will be performed orderly, isolated segment, acute reconnected segment , and unisolated segment will be also identified as described in phase I.~Usual ablation group:~Operator will be blinded to CF data, the procedure performance is the same as described in phase I.
Study NCT03236987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 1000 MG
Description: The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Clarithromycin, Ethambutol and Rifampicin.
Study NCT03236987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg
Description: The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Azithromycin, Ethambutol and Rifampicin.
Study NCT03236987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
Study NCT03236987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
Study NCT03236987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
Study NCT03236987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.